拉替拉韦与多替拉韦对HIV-2整合酶新型治疗相关突变谱的活性:基于扩展定点突变面板的表型分析
研究通过系统检索GenBank和HIV-2耐药文献,构建了95个HIV-2ROD9整合酶单/多氨基酸突变株,用单周期指示细胞试验检测其对拉替拉韦和多替拉韦的敏感性。结果显示两种药物在HIV-2ROD9中存在广泛交叉耐药,新鉴定的HIV-2特异性整合酶突变可显著提高EC50,编码G118R或231位SREGK/SREGR插入的变异对两种整合酶抑制剂均耐药。
要点
- 拉替拉韦与多替拉韦在HIV-2ROD9中存在广泛交叉耐药。
- Q91R、E92A、A153G、H157Q/S等新突变可显著提高拉替拉韦EC50。
- E92A/Q、T97A、G140A/S可增强多替拉韦耐药,G118R或231位插入对两者均耐药。
核心结论
- 分析表明新型整合酶抑制剂相关突变对HIV-2中拉替拉韦和多替拉韦耐药有贡献,这些发现应有助于改进HIV-2感染者的基因型耐药检测算法。
研究设计与样本
- 通过系统检索GenBank和HIV-2耐药文献鉴定治疗相关突变,构建了95个HIV-2ROD9整合酶单或多氨基酸突变株库,用单周期指示细胞试验检测每个变异对拉替拉韦和多替拉韦的敏感性。
主要发现
- 在HIV-2ROD9中观察到拉替拉韦和多替拉韦之间广泛的交叉耐药。
- HIV-2特异性整合酶突变Q91R、E92A、A153G和H157Q/S在引入1个或多个突变背景时显著提高拉替拉韦的半数最大有效浓度(EC50)。
- 突变E92A/Q、T97A和G140A/S对多替拉韦耐药呈现类似的增强作用。
- 编码G118R单独突变、或231位插入SREGK或SREGR残基的HIV-2ROD9变异对两种整合酶抑制剂均耐药。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Integrase inhibitors (INIs) are a key component of antiretroviral therapy for human immunodeficiency virus-1 (HIV-1) and HIV-2 infection. Although INI resistance pathways are well-defined for HIV-1, mutations that emerge in HIV-2 in response to INIs are incompletely characterized. METHODS: We performed systematic searches of GenBank and HIV-2 drug resistance literature to identify treatment-associated mutations for phenotypic evaluation. We then constructed a library of 95 mutants of HIV-2ROD9 that contained single or multiple amino acid changes in the integrase protein. Each variant was tested for susceptibility to raltegravir and dolutegravir using a single-cycle indicator cell assay. RESULTS: We observed extensive cross-resistance between raltegravir and dolutegravir in HIV-2ROD9. HIV-2-specific integrase mutations Q91R, E92A, A153G, and H157Q/S, which have not been previously characterized, significantly increased the half maximum effective concentration (EC50) for raltegravir when introduced into 1 or more mutational backgrounds; mutations E92A/Q, T97A, and G140A/S conferred similar enhancements of dolutegravir resistance. HIV-2ROD9 variants encoding G118R alone, or insertions of residues SREGK or SREGR at position 231, were resistant to both INIs. CONCLUSIONS: Our analysis demonstrates the contributions of novel INI-associated mutations to raltegravir and dolutegravir resistance in HIV-2. These findings should help to improve algorithms for genotypic drug resistance testing in HIV-2-infected individuals.
引用
- Smith RA, Wu VH, Song J, et al. Spectrum of Activity of Raltegravir and Dolutegravir Against Novel Treatment-Associated Mutations in HIV-2 Integrase: A Phenotypic Analysis Using an Expanded Panel of Site-Directed Mutants. J Infect Dis. 2022. PMID: 35134180. doi:10.1093/infdis/jiac037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。